Psychiatry
Tardive Dyskinesia
Expert Roundtables Podcast: The Differential Diagnosis of Drug-Induced Movement Disorders
Overview
The differential diagnosis of drug-induced movement disorders can be challenging, as these disorders may present with similar symptoms, or multiple disorders may coexist in the same patient. While tardive dyskinesia can often be managed in psychiatric settings, a collaboration between psychiatrists and neurologists becomes important when symptoms are complex or to rule out conditions such as Parkinson’s disease. As noted by our experts in today’s podcast, caregivers can play a key role in recognizing abnormal movements.
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.
Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401-415. doi:10.1017/S1092852922000992
Chouksey A, Pandey S. Clinical spectrum of drug-induced movement disorders: a study of 97 patients. Tremor Other Hyperkinet Mov (N Y). 2020;10:48. doi:10.5334/tohm.554
Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10-16. doi:10.1016/j.jns.2018.02.008
Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27(2):208-217. doi:10.1017/S109285292000200X
Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79(2):nu17034ah1c. doi:10.4088/JCP.nu17034ah1c
Kremens DE. Earlier diagnosis of tardive dyskinesia. J Clin Psychiatry. 2019;81(1):NU18041BR1C. doi:10.4088/JCP.NU18041BR1C
Loonen AJ, Ivanova SA. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. J Psychopharmacol. 2021;35(1):3-14. doi:10.1177/0269881120944156
Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. J Clin Psychopharmacol. 2019;39(4):336-343. doi:10.1097/JCP.0000000000001061
Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia—key differences in pathophysiology and clinical management. Neurol Ther. 2018;7(2):233-248. doi:10.1007/s40120-018-0105-0
Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401-415. doi:10.1017/S1092852922000992
Chouksey A, Pandey S. Clinical spectrum of drug-induced movement disorders: a study of 97 patients. Tremor Other Hyperkinet Mov (N Y). 2020;10:48. doi:10.5334/tohm.554
Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10-16. doi:10.1016/j.jns.2018.02.008
Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27(2):208-217. doi:10.1017/S109285292000200X
Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79(2):nu17034ah1c. doi:10.4088/JCP.nu17034ah1c
Kremens DE. Earlier diagnosis of tardive dyskinesia. J Clin Psychiatry. 2019;81(1):NU18041BR1C. doi:10.4088/JCP.NU18041BR1C
Loonen AJ, Ivanova SA. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. J Psychopharmacol. 2021;35(1):3-14. doi:10.1177/0269881120944156
Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. J Clin Psychopharmacol. 2019;39(4):336-343. doi:10.1097/JCP.0000000000001061
Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia—key differences in pathophysiology and clinical management. Neurol Ther. 2018;7(2):233-248. doi:10.1007/s40120-018-0105-0
